Vincent Albrecht

Vincent Albrecht

Auto-generated profile, based on publicly available information

Vincent Albrecht

Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJulia P. Schessner
Julia P. Schessner
VAVincent Albrecht
Vincent Albrecht
ADAlexandra K. Davies
Alexandra K. Davies
PSPavel Sinitcyn
Pavel Sinitcyn
GBGeorg H. H. Borner
Georg H. H. Borner
The Dynamic Organellar Maps (DOMs) approach combines cell fractionation and shotgun-proteomics for global profiling analysis of protein subcellular localization. Here, we enhance the performance of DOMs through data-independent acquisition (DIA) mass spectrometry. DIA-DOMs achieve twice the depth of our previous workflow in the same mass spectrometry runtime, and substantially improve profiling precision and reproducibility. We leverage this gain to establish flexible map formats scaling from high-throughput analyses to extra-deep coverage. Furthermore, we introduce DOM-ABC, a powerful and user-friendly open-source software tool for analyzing profiling data. We apply DIA-DOMs to capture subcellular localization changes in response to starvation and disruption of lysosomal pH in HeLa cells, which identifies a subset of Golgi proteins that cycle through endosomes. An imaging time-course reveals different cycling patterns and confirms the quantitative predictive power of our translocation analysis. DIA-DOMs offer a superior workflow for label-free spatial proteomics as a systematic phenotype discovery tool.

2 April 2024 in Communications Medicine
Verified
Journal Article
Open access
PDF file
CFClaudia Fredolini
Claudia Fredolini
TDTea Dodig-Crnković
Tea Dodig-Crnković
ABAnnika Bendes
Annika Bendes
LDLeo Dahl
Leo Dahl
MDMatilda Dale
Matilda Dale
JSJochen Schwenk
Jochen Schwenk
Background: Self-sampling of dried blood spots (DBS) offers new routes to gather valuable health-related information from the general population. Yet, the utility of using deep proteome profiling from home-sampled DBS to obtain clinically relevant insights about SARS-CoV-2 infections remains largely unexplored.Methods: Our study involved 228 individuals from the general Swedish population who used a volumetric DBS sampling device and completed questionnaires at home during spring 2020 and summer 2021. Using multi-analyte COVID-19 serology, we stratified the donors by their response phenotypes, divided them into three study sets, and analyzed 276 proteins by proximity extension assays (PEA). After normalizing the data to account for variances in layman-collected samples, we investigated the association of DBS proteomes with serology and self-reported information.Results: Our three studies display highly consistent variance of protein levels and share associations of proteins with sex (e.g., MMP3) and age (e.g., GDF-15). Studying seropositive (IgG+) and seronegative (IgG-) donors from the first pandemic wave reveals a network of proteins reflecting immunity, inflammation, coagulation, and stress response. A comparison of the early-infection phase (IgM+IgG-) with the post-infection phase (IgM-IgG+) indicates several proteins from the respiratory system. In DBS from the later pandemic wave, we find that levels of a virus receptor on B-cells differ between seropositive (IgG+) and seronegative (IgG-) donors.Conclusions: Proteome analysis of volumetric self-sampled DBS facilitates precise analysis of clinically relevant proteins, including those secreted into the circulation or found on blood cells, augmenting previous COVID-19 reports with clinical blood collections. Our population surveys support the usefulness of DBS, underscoring the role of timing the sample collection to complement clinical and precision health monitoring initiatives.

12 September 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
KKKathrin Korff
Kathrin Korff
JMJohannes B Müller-Reif
Johannes B Müller-Reif
DFDorothea Fichtl
Dorothea Fichtl
VAVincent Albrecht
Vincent Albrecht
ASAlicia-Sophie Schebesta
Alicia-Sophie Schebesta
PGPhilipp E Geyer
Philipp E Geyer
Bead-based enrichment is a promising strategy to improve depth in plasma proteomics by overcoming the dynamic range barrier. However, its robustness against pre-analytical variation has not been sufficiently characterized. Here, we systematically evaluate five plasma proteomics workflows, including three bead-based methods, a neat workflow, and a precipitation protocol using spike-ins of low-abundance proteins and defined cellular contaminants. We find that bead-based approaches enhance detection of low-abundance proteins but can be highly susceptible to systematic bias from platelet and PBMC contamination. This can inflate results by thousands of proteins, potentially explaining some of the high literature-reported numbers. A perchloric acid-based workflow shows resistance to erythrocyte and platelet-derived contamination. We investigate how centrifugation conditions, anticoagulant choice, and buffer-bead combinations modulate contamination profiles and demonstrate that bias can be mitigated by optimized sample handling. Altogether, we identify more than 13,000 different protein groups, including cellular components from the circulating proteome. Our results provide a quantitative framework for assessing workflow performance under variable sample quality and offer guidance for both biomarker discovery and quality control in clinical proteomics studies.

9 November 2024 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
VAVincent Albrecht
Vincent Albrecht
JMJohannes Müller-Reif
Johannes Müller-Reif
TNThierry M. Nordmann
Thierry M. Nordmann
AMAndreas Mund
Andreas Mund
LSLisa Schweizer
Lisa Schweizer
MMMatthias Mann
Matthias Mann
The 68th Benzon Foundation Symposium brought together leading experts to explore the integration of mass spectrometry–based proteomics and artificial intelligence to revolutionize personalized medicine. This report highlights key discussions on recent technological advances in mass spectrometry–based proteomics, including improvements in sensitivity, throughput, and data analysis. Particular emphasis was placed on plasma proteomics and its potential for biomarker discovery across various diseases. The symposium addressed critical challenges in translating proteomic discoveries to clinical practice, including standardization, regulatory considerations, and the need for robust “business cases” to motivate adoption. Promising applications were presented in areas such as cancer diagnostics, neurodegenerative diseases, and cardiovascular health. The integration of proteomics with other omics technologies and imaging methods was explored, showcasing the power of multimodal approaches in understanding complex biological systems. Artificial intelligence emerged as a crucial tool for the acquisition of large-scale proteomic datasets, extracting meaningful insights, and enhancing clinical decision-making. By fostering dialog between academic researchers, industry leaders in proteomics technology, and clinicians, the symposium illuminated potential pathways for proteomics to transform personalized medicine, advancing the cause of more precise diagnostics and targeted therapies.

26 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
VAVincent Albrecht
Vincent Albrecht
JMJohannes B. Müller-Reif
Johannes B. Müller-Reif
VBVincenth Brennsteiner
Vincenth Brennsteiner
MMMatthias Mann
Matthias Mann
Large scale plasma proteomics studies offer tremendous potential for biomarker discovery but face significant challenges in balancing analytical depth, throughput and cost-effectiveness. We present an optimized perchloric acid-based workflow with neutralization – PCA-N – that addresses these limitations. By introducing a neutralization step following protein precipitation, PCA-N enables direct enzymatic digestion without additional purification steps, reducing sample volume requirements to only 5 µL of plasma while maintaining deep plasma proteome coverage. The streamlined protocol allows preparation of over 10,000 samples per day using 384-well formats at costs comparable to undepleted plasma analysis (NEAT). Rigorous validation according to the recently introduced CLSI C64 guideline demonstrated that despite somewhat higher technical variability compared to NEAT, PCA-N maintained excellent biological resolution and reproducibility. We confirmed the workflow’s exceptional stability through analysis of 1,500 quality control samples systematically interspersed among 36,000 plasma samples measured continuously over 311 days. Technical performance remained consistent across multiple instruments, sample preparation batches and nearly a year of measurements. Compared to NEAT plasma proteomics, PCA-N doubled the proteomic depth while maintaining comparable reagent costs and throughput. The minimal sample reequipments, operational simplicity while using only common laboratory chemical and exceptional scalability positions PCA-N as an attractive approach for population-level plasma proteomics, democratizing access to deep plasma proteome analysis. Highlights: Perchloric acid with neutralization (PCA-N) allows drastic upscaling of plasma proteomics Minimal sample input (5 µL) in 384-well format enables thousands of samples processed daily PCA-N democratizes deep plasma proteomics using only common chemicals Validation per CLSI C64 demonstrates excellent repeatability and reproducibility PCA-N showed exceptional stability across 311 days of continuous MS acquisition Graphical

27 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJohannes B. Müller-Reif
Johannes B. Müller-Reif
VAVincent Albrecht
Vincent Albrecht
VBVincenth Brennsteiner
Vincenth Brennsteiner
JBJakob M. Bader
Jakob M. Bader
PTPeter V. Treit
Peter V. Treit
MMMatthias Mann
Matthias Mann
Mass spectrometry (MS)-based proteomics provides deep molecular insights from patient samples, but clinical use has been limited by missing values, static biomarker panels, and the need for targeted assay development. We present a framework – Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry (ADAPT-MS) – that enables direct diagnostic and prognostic interpretation of discovery-mode proteomics data at the level of individual samples. ADAPT-MS dynamically retrains simple, robust classifiers based on the proteins quantified in each sample, eliminating the need for imputation or fixed panels. Applied to plasma and cerebrospinal fluid datasets across diseases and clinical centers, it achieves high performance and generalizability using robust, transparent and generalizable statistical models. A single proteomic measurement can support multiple diagnostic questions via retrospective cohort matching, with each classification taking only seconds. As population-scale proteomics datasets grow, this approach lays the foundation for scalable, real-time, and personalized diagnostics directly from proteome-wide data. Such a community effort may help to transform discovery proteomics into a routine clinical tool.